Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Prox1 and oscillatory shear stress in aortic valve development and homeostasis

Award Number: F31HL150935
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 12/10/2019
PERIOD OF PERFORMANCE END DATE: 12/09/2022

Group Awards By:

View Award Description

Prox1 and oscillatory shear stress in aortic valve development and homeostasis - Project Summary Congenital aortic valve malformations, including bicuspid aortic valve, occur in approximately 2% of live births, and acquired heart valve diseases, such as calcific aortic valve disease, occur in about 2.5% of the U.S. population. It is theorized that mechanical forces influence both congenital and adult valve disease. Recently phenotypic and transcriptionally diverse aortic valve (AoV) cell populations were identified using single-cell RNA sequencing of maturing murine aortic and mitral valves. For the first time, three distinct valve endothelial cell (VEC) populations were identified in specific locations on the AoV. Each location experiences a unique combination of mechanical forces which could be important in diversifying VEC subpopulations. Importantly, one of these populations is present on the fibrosa side of the AoV where the VECs experience OSS. This population preferentially expresses the transcription factor Prox1, a master regulator of developmental processes, including cell fate and gene expression, in multiple organ systems. In the lymphatic system, Prox1 acts as a key regulator of lymphatic valve (LymphV) development and homeostasis in response to OSS. As Prox1 is present on the fibrosa side of murine embryonic day (E)13.5 semilunar valves and Prox1 remains present into adulthood, it is predicted that a similar mechanism is active during AoV development and homeostasis. The central hypothesis of this proposal is that Prox1 mediates aortic valve morphogenesis and homeostasis in response to changes in shear stress. Aim 1 will determine if fibrosa side-specific Prox1 promotes morphogenesis and homeostasis in the aortic valve by analyzing the expression pattern of Prox1 in the AoV of embryonic and adult mice throughout valve development and homeostasis. In parallel, the expression pattern of Gata2 and Cx37, Prox1’s inducer and downstream target in LymphV endothelial cells respectively, will also be analyzed (1A). Additionally, embryonic and adult endothelial-specific Prox1 loss-of-function mice will be utilized to study the effect Prox1 deletion has on Gata2 and Cx37 expression, as well as on valve morphology (1B). In Aim 2, the effects of altered shear stress on a Prox1 regulatory network and its relationship to valve homeostasis and disease will be analyzed. First, the expression pattern of Prox1, its lymphatic inducer (Gata2) and downstream target (Cx37) will be examined in porcine AoVs and in healthy and diseased human AoVs (2A). Next, the impact of physiologically relevant aberrant shear stress patterns on Prox1 in porcine AoV leaflets cultured ex vivo will be studied using a single cone-and-plate bioreactor (2B). Our long-term goal is to identify mechanosensitive mechanisms of AoV development, homeostasis and disease with potential therapeutic applications. This training plan combines studies of valve biology and bioengineering with translational implications. My career goal is to become a leader in understanding how the mechanical environment influences cardiovascular development, homeostasis and disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$10,160 )
2024	2022	CHILDRENS HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	000	3	10/27/2023	NON-COMPETING CONTINUATION	-$10,160
														Subtotal = -$10,160

Issue Date FY: 2022 ( Subtotal = $39,433 )
2022	2022	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	001	3	6/24/2022	NON-COMPETING CONTINUATION	$716
2022	2022	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	000	3	12/3/2021	NON-COMPETING CONTINUATION	$38,717
														Subtotal = $39,433

Issue Date FY: 2021 ( Subtotal = $38,717 )
2021	2021	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	001	2	3/15/2021	NON-COMPETING CONTINUATION	$516
2021	2021	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	000	2	11/23/2020	NON-COMPETING CONTINUATION	$38,201
														Subtotal = $38,717

Issue Date FY: 2020 ( Subtotal = $38,201 )
2020	2020	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	002	1	4/10/2020	NEW	$0
2020	2020	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	001	1	4/10/2020	NEW	$504
2020	2020	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	000	1	12/10/2019	NEW	$37,697
														Subtotal = $38,201

Grand Total All Awards = $106,191

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prox1 and oscillatory shear stress in aortic valve development and homeostasis

Award Number: F31HL150935

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 12/10/2019

PERIOD OF PERFORMANCE END DATE: 12/09/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer